查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853306

前列腺健康市場按產品類型、適應症、最終用戶、分銷管道和技術類型分類－2025-2032年全球預測

Prostate Health Market by Product Type, Indication, End User, Distribution Channel, Technology Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，攝護腺健康市場將成長至 1,336.3 億美元，複合年成長率為 11.12%。

關鍵市場統計數據
基準年 2024 574.8億美元
預計年份：2025年 638.8億美元
預測年份 2032 1336.3億美元
複合年成長率 (%) 11.12%

本書以清晰、實用的方式介紹了臨床、技術和商業性力量如何共同作用，重塑前列腺醫療保健服務和創新。

前列腺健康處於臨床緊迫性、技術創新和不斷變化的醫療保健系統優先事項的交匯點。診斷、分子分析和影像技術的進步正在重新定義臨床醫生檢測、表徵和管理前列腺疾病的方式，而人口趨勢和不斷發展的治療路徑也在再形成需求。本執行摘要總結了診斷套件、治療方法、影像技術以及醫療服務環境方面最重要的進展，旨在為價值鏈上各相關人員的策略選擇提供參考。

本分析旨在為臨床領導者、產品團隊和商業策略家提供簡潔、基於實證的指導，闡述新興能力和市場動態。它並非預測未來，而是著重強調變革促進因素、營運風險以及企業可以立即採取行動的優先機會。分析重點在於臨床檢驗路徑、技術整合挑戰、報銷和採購現狀，以及影響產品供應和成本狀況的供應鏈因素。

本摘要始終著重於實務：明確臨床需求、監管趨勢和技術成熟度之間的交匯點，闡明相關人員必須提升自身能力以獲取價值的領域，以及診斷、治療和影像服務提供者之間的合作如何才能對患者和醫療保健系統產生最大影響。接下來的章節將詳細闡述這些領域，以支持明智的決策。

對正在重新定義前列腺疾病診斷和治療方法的基本技術、臨床和系統層面的轉變進行深入分析

攝護腺健康領域正受到多種因素的共同影響，這些因素波及到醫療服務鏈的每一個環節。檢測靈敏度和分子診斷技術的進步使得早期發現和更精細的風險分層成為可能，而影像技術和放射性配體療法則正在改變診斷路徑和治療選擇。同時，數位病理學和人工智慧驅動的影像分析提高了診斷效率，並實現了遠距專家會診。

同時，患者的偏好和醫療系統的獎勵正朝著創傷較小的診斷、個人化的治療方法和以結果主導的照護模式發展。這需要整合高靈敏度PSA檢測、生物標記檢測和影像平台等綜合解決方案，以減少不必要的切片檢查，並引導患者選擇最合適的治療路徑。新型放射性藥物和診療一體化方法的出現進一步模糊了診斷和標靶治療之間的界限，促進了影像專家和腫瘤學家之間的跨學科合作。

監管機構越來越接受真實世界數據和伴隨診斷產生的證據，加速了診斷和治療一體化解決方案的進展。隨著醫療路徑的演變，那些能夠實現臨床檢驗、臨床醫生培訓和支付方參與等無縫工作流程的市場參與企業將從中受益。值得注意的是，不同地區和醫療環境下的技術應用並不均衡，因此，可行的策略必須充分考慮當地的報銷環境、醫療服務提供者的能力以及供應鏈的實際情況。

全面分析貿易政策和關稅如何再形成前列腺醫療技術的供應鏈、採購選擇和成本動態

與關稅相關的政策變化可能會對前列腺疾病治療中使用的資本設備、診斷劑和放射性藥物成分的供應和成本結構產生重大影響。更高的關稅可能會推高影像系統、PET示蹤劑和進口診斷試劑套件的到岸價格，迫使採購團隊重新評估採購計畫或加速用國產替代品替換現有產品。為此，一些醫療機構可能會優先採購可進行模組化升級或本地維護的設備，從而降低因關稅而產生的重複性成本。

對於擁有海外生產或單一供應商的製造商而言，關稅加上不斷變化的貿易政策，會加劇供應鏈風險。這些動態促使企業加大對多元化籌資策略、關鍵零件製造近岸外包以及關鍵試劑和影像處理劑替代供應商資質認證的投資。對於PET和MRI平台等高價值技術而言，服務合約和備件物流正日益成為總擁有成本計算的核心，採購談判也擴大納入關稅轉嫁條款和外匯對沖策略。

關稅主導的成本壓力也將影響通路。醫院藥局和診斷實驗室可能會調整進口試劑套件和放射性藥物的購買方式，而線上和線下藥局可能會重新評估其定價模式。臨床醫生和醫療系統可能會透過採用本地可用的檢測方法或優先考慮減少重複影像檢查需求的技術來應對。最終，到2025年，關稅的累積效應將加速向更具韌性的供應鏈、靈活的製造地和更強大的商業夥伴關係的策略轉變，以維持醫療服務的可及性並控制成本。

深入的細分分析揭示了產品類型、臨床適應症、醫療機構、通路和實行技術如何相互交織，從而塑造機會。

精細的細分視角揭示了不同產品系列、適應症、醫療環境、通路和實行技術在臨床需求和機會方面的交集。按產品類型分類，診斷試劑套件包括切片檢查設備、顯影劑和PSA檢測。 PSA檢測本身又分為常規檢測和高靈敏度檢測，二者在篩檢、監測和復發檢測中發揮不同的臨床作用。藥物涵蓋化療、荷爾蒙療法、免疫療法和放射性藥物。荷爾蒙療法又分為雄性激素受體拮抗劑和促性腺激素釋放激素（LHRH）促效劑，這反映了不同的處方模式和監測需求。顯像系統包括電腦斷層掃描（CT）、磁振造影）、正子斷層掃描（PET）和超音波。在超音波領域，經腹和經直腸入路的差異會影響手術流程和病患的接受度。

從適應症來看，良性前列腺增生、前列腺癌和前列腺炎的臨床病程各不相同，每種疾病都需要不同的診斷和治療方案，因此需要為臨床醫生製定量身定做的教育和患者互動策略。從最終用戶來看，門診醫療中心、診斷實驗室、醫院和專科診所的採購週期、監管限制和工作流程整合需求各不相同。這些差異會影響產品設計、服務組合和培訓重點。分銷管道也多種多樣——包括直銷、醫院藥房、線上藥房和零售藥房——這些都會影響庫存管理、價格談判和患者就醫途徑。

按技術類型進行細分，凸顯了數位病理學、影像分析軟體和分子診斷日益成長的重要性。數位病理學分為基於人工智慧的分析和全切片成像，從而實現遠端專家審核和演算法分診。生物標記檢測（如PCA3和TMPRSS2-ERG）支援分子風險分層，而PCR檢測則分為數位PCR和即時PCR，分別適用於不同的靈敏度、通量和實驗室基礎設施要求。這些細分維度共同明確了產品開發、臨床檢驗和商業性工作的重點方向，以滿足整個醫療服務鏈中不同的需求。

美洲、歐洲、中東和非洲以及亞太市場在採用模式、法規環境和商業化策略方面的區域觀點

區域動態對前列腺癌技術的採納模式、監管時間表和商業化策略有顯著影響。在美洲，科技的採納往往受到整合醫療體系、支付方動態以及對基於價值的治療結果的關注所驅動，這些因素促使人們傾向於選擇能夠降低後續成本並提高診斷準確性的技術。該地區的臨床網路和集中式實驗室能夠快速擴大分子檢測和整合影像服務的規模，但採購週期和報銷政策需要支付方的積極參與以及可靠的衛生經濟學證據。

在歐洲、中東和非洲地區，監管路徑、公共採購慣例和基礎設施成熟度的差異導致了不同地區的技術採納速度各不相同。一些國家正在加速採用先進的影像和分子診斷技術，其他國家則以集中式癌症中心和國家篩檢計畫為驅動，還有一些市場優先考慮成本效益高的篩檢和廣泛的PSA檢測。市場參與企業需要結合公開競標、私人醫療服務網路和區域性臨床指南才能獲得市場認可。

在亞太地區，龐大的患者群體、不斷擴展的診斷能力以及對專科醫療投入的增加，為照護現場診斷和高階影像解決方案的發展創造了沃土。然而，分散的醫保報銷系統和多樣化的實驗室基礎設施意味著，將集中式參考檢測與本地即時診斷相結合的混合商業化模式往往能取得最佳效果。該地區成功的策略是將產品設計和證據生成與當地的臨床工作流程和醫保報銷實際情況相契合，同時利用夥伴關係關係來彌補能力缺口。

公司層面的策略洞察揭示了產品整合、證據產生和營運韌性如何為前列腺醫療保健生態系統創造差異化優勢。

為了增強自身競爭力，前列腺醫療保健生態系統中的主要企業正致力於技術整合、策略夥伴關係和實證實踐相結合。許多企業正在將診斷和影像設備與臨床決策支援工具和數位平台整合，以簡化工作流程、降低診斷不確定性並支援多學科治療路徑。這超越了簡單的產品捆綁銷售，而是與實驗室網路、影像中心和專科診所建立合作關係，以確保端到端的服務交付並促進結果研究的資料收集。

研發重點與臨床需求保持一致，包括開發高靈敏度檢測方法、檢驗分子生物標記作為伴隨診斷的有效性，以及開發結合放射性藥物和影像技術的治療策略。各公司也正在增加對監管資訊和支付方策略能力的投入，以加速報銷核准並證明其療效優於其他療法。在營運方面，各公司正在加強生產韌性和服務網路，以確保關鍵試劑和設備的穩定供應，尤其是在近期貿易和物流中斷的情況下。

商業領導者正透過臨床醫生教育計畫、真實世界證據舉措和在地化部署模式來脫穎而出。他們越來越注重擴充性的培訓、遠端支援工具和靈活的銷售條款，以降低採用門檻，尤其是在複雜的醫院和專科診所環境中。最終，能夠兼顧臨床信譽、可靠供應和清晰的價值主張（面向醫療服務提供者和支付方）的機構才能獲得競爭優勢。

為商業、臨床和營運領導者提供切實可行的、優先排序的建議，以加速前列腺護理市場的推廣應用並增強其韌性。

產業領導者應優先採取一系列切實可行的措施，在抓住短期機會的同時，建構長期韌性。首先，投資高靈敏度PSA檢測法和分子生物標記檢測的臨床檢驗，以減少不必要的侵入性手術，並實現更精準的監測。其次，透過對替代供應商進行資格認證、評估關鍵零件的近岸外包方案，以及建構共用關稅和外匯風險的商業協議，來增強供應鏈韌性，從而保障利潤率並維持服務水準。

第三，我們將致力於開發整合影像系統、影像分析軟體和診斷平台的一體化解決方案，以創建無縫的臨床工作流程。這需要與影像中心、診斷實驗室和專科診所建立夥伴關係，並提供培訓和遠端支持，以確保快速成功地應用這些方案。第四，我們將針對醫院藥局、直接競標、線上藥局和零售商制定差異化的分銷策略，使合約和服務水準與各通路獨特的採購和庫存管理方式相符。第五，我們將加強對臨床醫生和患者的教育投入，以提高他們對新診斷路徑的接受度，重點強調新方法如何減少過度治療、提高生活品質，並支持醫患共用決策。

最後，將經濟模型和真實世界證據收集納入產品上市流程，以向支付方和醫療服務提供者展示產品價值，並實施靈活的商業性試點項目，以測試定價、捆綁銷售和報銷模式。這些措施將有助於改善市場進入，促進產品普及，並降低營運衝擊帶來的風險。

本文對一種混合方法調查方法進行了清晰的闡述，該策略結合了文獻綜述、專家訪談和供應鏈圖譜分析，旨在獲得可操作的策略見解。

本研究綜合了已發表的臨床文獻、監管文件、產品標籤和同行評審研究，並輔以對臨床醫生、實驗室主任、採購專業人員和行業專家的定性訪談。研究方法結合了對臨床和商業性趨勢的主題分析以及供應鏈圖譜分析，以識別瓶頸和風險點。關於診斷性能和臨床效用的證據來自多個資訊來源，並經過三角驗證以檢驗其有效性，同時評估其在不同醫療保健環境中的相關性。

為了解實施過程中遇到的挑戰、採購行為以及臨床醫生教育的優先事項，我們開展了專家訪談；同時，技術實施案例研究也為我們提供了關於整合時間表和培訓需求的實用見解。此外，我們還審查了監管和報銷框架，以確定影響核准途徑和實施時間的支付方考量。在條件允許的情況下，我們將調查結果與公開的臨床試驗註冊資訊、指南更新和產品技術文獻進行交叉核對，以確保其準確性。

透過交叉檢驗假設、透明記錄資料來源以及反覆的同儕評審，確保了分析的嚴謹性。針對報告標準的區域差異和臨床實踐模式的異質性等局限性，調查方法強調對可操作證據的解讀，以支持策略和營運決策。

簡潔扼要的結論強調了診斷、影像和營運韌性的整合是改善攝護腺疾病診療路徑和策略行動的基礎。

攝護腺健康正步入一個新階段，診斷準確性、影像創新和整合式診療路徑的融合有望改善患者預後並更有效地利用醫療系統資源。高靈敏度檢測、分子診斷、先進影像和數位病理學的融合，為減少不必要的手術、個人化治療方案的選擇以及提供更可預測的診療過程創造了機會。同時，不斷變化的貿易政策和物流壓力凸顯了營運韌性和靈活的商業化策略的重要性。

相關人員協調臨床檢驗和報銷證據、投資於互通技術和臨床醫生培訓、並積極確保供應鏈多元化的利益相關者，最能將創新轉化為持續的臨床和商業性影響。在強力的真實世界證據的支持下，診斷、影像和治療領域的合作將加速診斷和治療一體化路徑的採用，從而實現以患者為中心的醫療服務。領導者亟需迅速將洞察轉化為行動，專注於初步試驗，以檢驗工作流程整合並為規模化生產奠定經濟基礎。

本執行摘要提煉了指導此次轉型並幫助相關人員優先考慮能夠帶來臨床價值且降低營運風險的投資的核心主題。所提出的建議旨在支持基於實證醫學的決策，以改善前列腺疾病診療的可近性、品質和經濟效益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過引入先進的影像診斷方法，促進前列腺癌的早期發現。
  • 擴大遠端醫療和遠距監測服務在前列腺健康管理的應用
  • 針對前列腺健康需求的個人化營養補充品的出現
  • 將人工智慧和機器學習演算法整合到前列腺癌的診斷和預後中
  • 微創局部療法的日益普及可減少治療後的副作用
  • 面向消費者的前列腺癌風險篩檢基因檢測激增
  • 影響常規前列腺特異性抗原篩檢通訊協定的監管指南變更

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 攝護腺健康市場（依產品類型分類）

  • 診斷試劑套件
    • 切片檢查裝置
    • 造影
    • PSA檢測
      • 傳統的
      • 高靈敏度
  • 藥物
    • 化療
    • 荷爾蒙療法
      • 雄性激素受體拮抗劑
      • LHRH促效劑
    • 免疫療法
    • 放射性藥物
  • 影像系統
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
      • 經腹
      • 經直腸

9. 攝護腺健康市場（依適應症分類）

  • 良性攝護腺增生
  • 攝護腺癌
  • 攝護腺炎

10. 按最終用戶分類的前列腺健康市場

  • 門診治療中心
  • 診斷實驗室
  • 醫院
  • 專科診所

11. 前列腺健康市場按分銷管道分類

  • 直接競標
  • 醫院藥房
  • 網路藥房
  • 零售藥房

12. 依技術類型分類的前列腺健康市場

  • 數位病理學
    • 基於人工智慧的分析
    • 全切片成像
  • 影像分析軟體
  • 分子診斷
    • 生物標記檢測
      • PCA3
      • Tmprss2 erg
    • 次世代定序面板
    • 聚合酵素鏈鎖反應檢測
      • 數位PCR
      • 即時PCR

13. 各地區的攝護腺健康市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 前列腺健康市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國前列腺健康市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Bayer AG
    • Novartis AG
    • Ferring International Center SA
    • Ipsen SA
    • AbbVie Inc.
    • AstraZeneca PLC
    • Merck & Co., Inc.
Product Code: MRR-8201ABF20E0C

The Prostate Health Market is projected to grow by USD 133.63 billion at a CAGR of 11.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 57.48 billion
Estimated Year [2025] USD 63.88 billion
Forecast Year [2032] USD 133.63 billion
CAGR (%) 11.12%

A clear and practical introduction to the converging clinical, technological, and commercial forces reshaping prostate health care delivery and innovation

Prostate health sits at the intersection of clinical urgency, technological innovation, and shifting health-system priorities. Advances in diagnostics, molecular profiling, and imaging are redefining how clinicians detect, characterize, and manage prostate conditions, while demographic trends and evolving care pathways are reshaping demand. This executive summary synthesizes the most consequential developments across diagnostic kits, therapeutics, imaging modalities, and care delivery settings to inform strategic choices for stakeholders across the value chain.

The purpose of this analysis is to provide a concise, evidence-based orientation to emerging capabilities and market dynamics that matter for clinical leaders, product teams, and commercial strategists. Rather than presenting projections, the narrative highlights drivers of change, operational risks, and priority opportunities that organizations can act upon now. Emphasis is placed on clinical validation pathways, technology integration challenges, reimbursement and procurement realities, and supply-chain factors that influence product availability and cost profiles.

Throughout this summary, the focus remains practical: clarifying where clinical need, regulatory momentum, and technology readiness converge; where stakeholders must strengthen capabilities to capture value; and where collaborations between diagnostics, therapeutics, and imaging providers will deliver the highest impact for patients and health systems. The following sections unpack these areas to support informed decision making.

Detailed analysis of the fundamental technological, clinical, and system-level shifts that are redefining diagnosis and treatment approaches in prostate care

The landscape for prostate health is being transformed by multiple convergent forces that affect every link in the care continuum. Advances in assay sensitivity and molecular diagnostics are enabling earlier detection and finer risk stratification, while imaging technologies and radioligand therapies are shifting both diagnostic pathways and therapeutic options. At the same time, digital pathology and AI-fueled image analysis are accelerating diagnostic throughput and enabling remote expert review, which alters where and how care is delivered.

Simultaneously, patient preferences and health-system incentives are pushing toward less invasive diagnostics, personalized treatment regimens, and outcome-driven care models. This creates pressure for integrated solutions that combine high-sensitivity PSA tests, biomarker assays, and imaging platforms to reduce unnecessary biopsies and to direct patients to the most appropriate therapeutic pathway. The emergence of novel radiopharmaceuticals and theranostic approaches further blurs the line between diagnostics and targeted treatment, prompting cross-disciplinary collaboration between imaging specialists and oncologists.

Regulatory agencies are increasingly receptive to evidence generated by real-world data and companion diagnostics, which accelerates pathways for combined diagnostic-therapeutic solutions. Market participants who align clinical validation, clinician education, and payer engagement with seamless workflows stand to benefit as care pathways evolve. Importantly, technology adoption is uneven geographically and across care settings, so actionable strategies must account for local reimbursement climates, provider capabilities, and supply-chain realities.

Comprehensive examination of how trade policy and tariffs are reshaping supply chains, procurement choices, and cost dynamics across prostate health technologies

Policy shifts related to tariffs can materially influence the availability and cost structure of capital equipment, diagnostic reagents, and radiopharmaceutical components used in prostate care. Tariff increases can raise the landed cost of imaging systems, PET tracers, and imported diagnostic kits, prompting procurement teams to reassess purchasing schedules and to accelerate replacement timelines for domestic alternatives. In response, some providers may prioritize acquisition of equipment that offers modular upgrades or local serviceability to mitigate recurring tariff-driven cost exposure.

Manufacturers with offshore production or single-source suppliers can see supply-chain risk amplify when tariffs are coupled with shifts in trade policy. Such dynamics encourage investment in diversified sourcing strategies, nearshoring of critical component manufacturing, and qualification of alternate suppliers for key reagents and imaging agents. For high-value technologies such as PET and MRI platforms, service contracts and spare-parts logistics become central to total cost of ownership calculations, and procurement negotiations increasingly factor in tariff pass-through clauses and currency volatility hedging.

Tariff-driven cost pressure also affects distribution channels: hospital pharmacies and diagnostic laboratories may adjust stocking practices for imported kits and radiopharmaceuticals, while online and retail pharmacies could recalibrate pricing models. Clinicians and health systems may respond by adopting tests that can be performed locally or by prioritizing technologies that reduce the need for repeated imaging. Ultimately, the cumulative effect of tariffs in 2025 is to accelerate strategic shifts toward resilient supply chains, flexible manufacturing footprints, and stronger commercial partnerships to preserve access and control costs.

In-depth segmentation analysis revealing how product categories, clinical indications, care settings, distribution pathways, and enabling technologies intersect to shape opportunity

A granular segmentation lens clarifies where clinical need and commercial opportunity intersect across product families, indications, care settings, distribution pathways, and enabling technologies. Based on product type, diagnostic kits include biopsy devices, imaging agents, and PSA tests; PSA tests themselves divide into conventional assays and high-sensitivity formats, each with distinct clinical roles in screening, monitoring, and recurrence detection. Drugs span chemotherapy, hormone therapies, immunotherapies, and radiopharmaceuticals; hormone therapies differentiate between androgen receptor antagonists and LHRH agonists, which inform prescribing patterns and monitoring requirements. Imaging systems encompass computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound; within ultrasound the distinction between transabdominal and transrectal approaches affects procedural logistics and patient acceptance.

Examining indication reveals distinct clinical pathways for benign prostatic hyperplasia, prostate cancer, and prostatitis, with each condition driving demand for different diagnostic and therapeutic mixes and requiring tailored clinician education and patient engagement strategies. Considering end users highlights that ambulatory care centers, diagnostic laboratories, hospitals, and specialty clinics operate under varied procurement cycles, regulatory constraints, and workflow integration needs; these differences influence product design, service bundles, and training priorities. Distribution channels range from direct tender and hospital pharmacies to online and retail pharmacies, shaping inventory management, pricing negotiation, and patient access.

Technology type segmentation underscores the growing importance of digital pathology, image analysis software, and molecular diagnostics. Digital pathology splits into AI-based analysis and whole slide imaging, enabling remote expert review and algorithmic triage. Molecular diagnostics include biomarker tests, next-generation sequencing panels, and polymerase chain reaction assays; biomarker tests such as PCA3 and TMPRSS2-ERG support molecular risk stratification, while PCR assays divide into digital PCR and real-time PCR, each suited to different sensitivity, throughput, and laboratory infrastructure profiles. Together, these segmentation dimensions reveal where product development, clinical validation, and commercial efforts should be concentrated to meet differentiated needs across the care continuum.

Regional perspectives on adoption patterns, regulatory environments, and commercialization tactics across the Americas, Europe Middle East & Africa, and Asia Pacific markets

Regional dynamics materially affect adoption patterns, regulatory timelines, and commercial strategies for prostate health technologies. In the Americas, adoption is often driven by integrated health systems, payer negotiation dynamics, and a strong focus on value-based outcomes, which favors technologies that reduce downstream costs and improve diagnostic certainty. Clinical networks and centralized laboratories in this region enable rapid scale-up of molecular assays and consolidated imaging services, but procurement cycles and reimbursement policies require proactive payer engagement and robust health-economic evidence.

Across Europe, the Middle East & Africa, heterogeneity in regulatory pathways, public procurement practices, and infrastructure maturity leads to varied adoption curves. Certain countries demonstrate accelerated uptake of advanced imaging and molecular diagnostics where centralized cancer centers and national screening initiatives support adoption, while other markets prioritize cost-effective screening and widely deployable PSA testing. Market participants must navigate a mix of public tendering, private provider networks, and region-specific clinical guidelines to achieve traction.

In the Asia-Pacific region, a combination of large patient volumes, expanding diagnostic capacity, and increasing investment in specialty care creates fertile ground for both point-of-care diagnostics and high-end imaging solutions. However, fragmented reimbursement frameworks and variable laboratory infrastructure mean that hybrid commercialization approaches-combining centralized reference testing with local point-of-care options-often yield the best results. Across regions, successful strategies align product design and evidence generation to local clinical workflows and reimbursement realities while leveraging partnerships to bridge capability gaps.

Strategic company-level insights showing how product integration, evidence generation, and operational resilience are creating differentiation in the prostate health ecosystem

Leading organizations in the prostate health ecosystem are pursuing a combination of technology convergence, strategic partnerships, and evidence generation to strengthen competitive positioning. Many are integrating diagnostics and imaging offerings with clinical decision support tools and digital platforms to streamline workflows, reduce diagnostic uncertainty, and support multidisciplinary care pathways. This extends beyond product bundling toward partnerships with laboratory networks, imaging centers, and specialty clinics to ensure end-to-end service delivery and to facilitate data capture for outcomes studies.

Research and development priorities are aligning with clinical needs: advancing high-sensitivity assays, validating molecular biomarkers as companion diagnostics, and developing radiopharmaceuticals paired with imaging to enable theranostic strategies. Companies are also investing in regulatory intelligence and payer strategy capabilities to accelerate reimbursement approvals and to demonstrate comparative effectiveness. Operationally, firms are enhancing manufacturing resilience and service networks to ensure uninterrupted supply of critical reagents and equipment, particularly in light of recent trade and logistical disruptions.

Commercial leaders are differentiating through clinician education programs, real-world evidence initiatives, and locally adapted deployment models. They are increasingly focused on scalable training, remote support tools, and flexible commercial terms to lower barriers to adoption, especially in complex hospital and specialty clinic environments. Ultimately, competitive advantage accrues to organizations that combine clinical credibility, reliable supply, and a clear value articulation for providers and payers.

Actionable and prioritized recommendations for commercial, clinical, and operational leaders to accelerate adoption and strengthen resilience in prostate health markets

Industry leaders should prioritize a set of pragmatic actions to capture near-term opportunities while building long-term resilience. First, invest in clinical validation for high-sensitivity PSA assays and molecular biomarker tests that reduce unnecessary invasive procedures and enable more precise monitoring; aligning these studies with payer evidence requirements will streamline reimbursement conversations. Second, strengthen supply-chain resilience by qualifying alternate suppliers, evaluating nearshoring options for critical components, and structuring commercial agreements that share tariff and currency risks to protect margins and maintain service levels.

Third, pursue integrated solutions that combine imaging systems, image analysis software, and diagnostic platforms to create seamless clinical workflows. This requires building partnerships across imaging centers, diagnostic laboratories, and specialty clinics, and offering training and remote support to ensure rapid and correct adoption. Fourth, develop differentiated distribution strategies for hospital pharmacies, direct tenders, online pharmacies, and retail outlets, tailoring contracts and service levels to the unique procurement and inventory practices of each channel. Fifth, invest in clinician and patient education to increase acceptance of newer diagnostic pathways and to support shared decision making, emphasizing how new approaches can reduce overtreatment and improve quality of life.

Finally, embed economic modeling and real-world evidence collection into product launches to demonstrate value to payers and providers, and create flexible commercial pilots to test pricing, bundling, and reimbursement models. These actions together will improve market access, accelerate adoption, and reduce exposure to operational shocks.

Transparent explanation of the mixed-method research approach combining literature synthesis, expert interviews, and supply-chain mapping to produce actionable strategic insights

This research synthesized published clinical literature, regulatory documents, product labeling, and peer-reviewed studies, augmented by primary qualitative interviews with clinicians, laboratory directors, procurement specialists, and industry experts. The approach combined thematic analysis of clinical and commercial trends with targeted supply-chain mapping to identify bottlenecks and risk points. Evidence around diagnostic performance and clinical utility was triangulated across multiple sources to validate claims and to assess relevance across care settings.

Expert interviews were structured to capture implementation challenges, procurement behaviors, and priorities for clinician education, while case studies of technology deployments provided practical insight into integration timelines and training needs. Regulatory and reimbursement frameworks were reviewed to surface approval pathways and payer considerations that influence time-to-adoption. Wherever possible, findings were corroborated with publicly available clinical trial registries, guideline updates, and technical product literature to ensure accuracy.

Analytical rigor was maintained through cross-validation of hypotheses, transparent documentation of data sources, and iterative review with subject-matter experts. Limitations include variability in reporting standards across regions and heterogeneity in clinical practice patterns, which were addressed by presenting scenario-based implications rather than deterministic projections. The methodology emphasizes actionable interpretation of evidence to support strategy and operational decision making.

A concise conclusion highlighting convergence of diagnostics, imaging, and operational resilience as the foundation for improved prostate care pathways and strategic action

Prostate health is entering a phase in which diagnostic precision, imaging innovation, and integrated care pathways collectively promise better patient outcomes and more efficient use of health-system resources. The convergence of high-sensitivity assays, molecular diagnostics, advanced imaging, and digital pathology creates opportunities to reduce unnecessary procedures, personalize therapy selection, and deliver more predictable care journeys. At the same time, trade policy shifts and logistical pressures underscore the importance of operational resilience and flexible commercialization strategies.

Stakeholders that align clinical validation with reimbursement evidence, invest in interoperable technologies and clinician training, and proactively secure diversified supply chains will be best positioned to translate innovation into sustained clinical and commercial impact. Collaboration across diagnostics, imaging, and therapeutics sectors-supported by robust real-world evidence-will accelerate the adoption of combined diagnostic-therapeutic pathways and enable more patient-centric care. The imperative for leaders is to move quickly from insight to execution, focusing on pilots that validate workflow integration and build the economic case for scale.

This executive summary distills core themes to guide that transition and to help stakeholders prioritize investments that deliver clinical value while mitigating operational risk. The recommendations offered here are intended to support evidence-based decisions that improve access, quality, and affordability in prostate care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of advanced imaging modalities driving early prostate cancer detection
  • 5.2. Expansion of telehealth and remote monitoring services for prostate health management
  • 5.3. Emergence of personalized nutraceutical supplements tailored to prostate health needs
  • 5.4. Integration of AI and machine learning algorithms in prostate cancer diagnostics and prognostics
  • 5.5. Growing availability of minimally invasive focal therapies reducing post treatment side effects
  • 5.6. Surge in direct to consumer genetic testing offerings for prostate cancer risk screening
  • 5.7. Shifts in regulatory guidelines influencing routine prostate specific antigen screening protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Health Market, by Product Type

  • 8.1. Diagnostic Kits
    • 8.1.1. Biopsy Devices
    • 8.1.2. Imaging Agents
    • 8.1.3. Psa Tests
      • 8.1.3.1. Conventional
      • 8.1.3.2. High Sensitivity
  • 8.2. Drugs
    • 8.2.1. Chemotherapy
    • 8.2.2. Hormone Therapy
      • 8.2.2.1. Androgen Receptor Antagonists
      • 8.2.2.2. Lhrh Agonists
    • 8.2.3. Immunotherapy
    • 8.2.4. Radiopharmaceuticals
  • 8.3. Imaging Systems
    • 8.3.1. Computed Tomography
    • 8.3.2. Magnetic Resonance Imaging
    • 8.3.3. Positron Emission Tomography
    • 8.3.4. Ultrasound
      • 8.3.4.1. Transabdominal
      • 8.3.4.2. Transrectal

9. Prostate Health Market, by Indication

  • 9.1. Benign Prostatic Hyperplasia
  • 9.2. Prostate Cancer
  • 9.3. Prostatitis

10. Prostate Health Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Prostate Health Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Prostate Health Market, by Technology Type

  • 12.1. Digital Pathology
    • 12.1.1. Ai Based Analysis
    • 12.1.2. Whole Slide Imaging
  • 12.2. Image Analysis Software
  • 12.3. Molecular Diagnostics
    • 12.3.1. Biomarker Tests
      • 12.3.1.1. Pca3
      • 12.3.1.2. Tmprss2 Erg
    • 12.3.2. Next Generation Sequencing Panels
    • 12.3.3. Polymerase Chain Reaction Assays
      • 12.3.3.1. Digital Pcr
      • 12.3.3.2. Real Time Pcr

13. Prostate Health Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Health Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Health Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Astellas Pharma Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Bayer AG
    • 16.3.5. Novartis AG
    • 16.3.6. Ferring International Center S.A.
    • 16.3.7. Ipsen S.A.
    • 16.3.8. AbbVie Inc.
    • 16.3.9. AstraZeneca PLC
    • 16.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS PROSTATE HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS PROSTATE HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS PROSTATE HEALTH MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA PRO